Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib PK Study in HER2+ MBC
NCT04367090Phase 1Completed
- Sponsor
- Hengrui
- Start
- May 2020
- Primary completion
- Aug 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pyrotinib in breast cancer, sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration of Pyrotinib and Docetaxel at 2 months and Area Under the Curve of Pyrotinib and Docetaxel at 2 months. Started May 2020; status: completed.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04367090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04367090.